Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Acute Myeloid Leukemia | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2017

Login to access report north_east
Contact sales account_box

Acute myeloid leukemia is the most common form of acute leukemia in adults. Its incidence in the major pharmaceutical markets under study is increasing, largely as a result of the aging population.

A range of therapies are used to treat AML; however, the market is dominated by the use of agents that induce DNA damage. As drug treatments and clinical trial designs continue to evolve, novel agents with new mechanisms of action are set to enter this market.

Questions Answered:

  • The AML population will continue to grow during our forecast period due to population aging as well as population growth. What is the size of the U.S. and EU5 (France, Germany, Italy, Spain, and U.K.) AML populations, and how will they change over the forecast period?
  • Several drug classes are in late-stage development for AML, including kinase inhibitors, hypomethylating agents, nucleoside analogues, and anti-KIR agents. What do experts think about the prospects of emerging therapies? For which agents, if any, do we forecast a launch in AML, and how will they affect the AML landscape?
  • A high level of unmet need exists in AML for several key populations. What are the key unmet needs in AML treatment according to interviewed experts? Will any of these unmet needs be addressed during the next ten years?

Scope:

Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: Three key opinion leaders from the United States and five from Europe with expertise in AML treatment were interviewed for this report.

Epidemiology: Diagnosed incident cases of AML (excluding APL) and APL in the United States and EU5.

Population segments in market forecast: First-line AML (excluding APL), relapsed/refractory AML (excluding APL), first-line APL, relapsed/refractory APL.

Emerging therapies: Phase I/II: 4 drugs; Phase III: 8 drugs.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east